Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

Inclusion Criteria:

1. Patients of male and female gender aged 18 to 64 years.
2. Uncomplicated, moderate influenza supported by all the symptoms:

• axillary temperature ≥38.1°С on physician examination;
• at least one moderate general symptom of influenza infection (headache,fever/chill, aches in the muscles/joints, weakness/drowsiness);
• at least one moderate respiratory symptom of influenza infection (cough, sorethroat, or nasal congestion).

3. Positive influenza rapid test (detection of virus antigens in the nasal epithelium).
4. First 24 hours of the onset of illness.
5. Patients who agree to use a reliable method of birth control during the study.
6. Patients who have provided signed Participant Information Sheet and Informed Consentform to participate in a clinical trial.

Exclusion Criteria:

1. Severe influenza infection that requires hospitalization.
2. Suspected pneumonia or bacterial infection (including otitis media, sinusitis, urinarytract infection, meningitis, sepsis, etc.) that requires the use of antibiotics,starting from the first day of illness.
3. Suspected early manifestations of a condition that, on its first onset, producessymptoms similar to those of influenza (other infectious diseases and/orinfluenza-like syndrome associated with the first onset of a systemic connectivetissue disorder or another condition).
4. Patients who require the use of antivirals that are not permitted during the study.
5. Current season influenza vaccination.
6. Prior history or diagnosis of primary or secondary immunodeficiency
7. Patients with any known or suspected malignant neoplasm.
8. An exacerbated or decompensated chronic disease interfering with the subject'sparticipation in the clinical trial.
9. Malabsorption syndrome, including congenital or acquired lactase deficiency (or anyother disaccharidase deficiency), and/or galactosemia.
10. Current allergy to or intolerance of the active substances or any of the excipients inthe medications used in the treatment.
11. Pregnancy, breast-feeding, childbirth within less than 3 months prior to the inclusionin the trial, or unwillingness to use contraceptive methods during the study
12. Prior history of non-adherence to medication; mental disorder; or alcohol or substanceabuse, which, in the investigator's opinion, will compromise compliance with studyprocedures.
13. Use of any of the "Prohibited Concomitant Medications" within 2 weeks prior to studyentry.
14. Patients who, as judged by the investigator, will fail or be unwilling to comply withthe observation requirements or adhere to the dosing regimen during the study.
15. Participation in other clinical studies within 3 months prior to the inclusion in thisstudy.
16. Patients who are related to any of the on-site research personnel directly involved inthe conduct of the study or are an immediate relative of the investigator. 'Immediaterelative' means husband, wife, parent, son, daughter, brother, or sister (regardlessof whether they are natural or adopted).
17. Patients who work for OOO "NPF "Materia Medica Holding" (i.e. company employees,temporary contract workers, designated officials responsible for carrying out theresearch or any immediate relatives of the aforementioned).